Why the study?
The study was conducted to compare the safety and efficacy of long-term DAPT versus intensive rosuvastatin combined with short-term DAPT for acute ischemic stroke.
Does intensive rosuvastatin with short-term DAPT reduce recurrent ischemic stroke and hemorrhage compared to long-term DAPT in patients with mild to moderate acute ischemic stroke?
Does intensive rosuvastatin with short-term DAPT reduce recurrent ischemic stroke and hemorrhage compared to long-term DAPT in patients with mild to moderate acute ischemic stroke?
In patients with mild to moderate acute ischemic stroke, intensive rosuvastatin with 7-day DAPT significantly reduced bleeding risk without compromising efficacy against recurrent stroke compared to standard 21-day DAPT.
Answers are grounded in this paper and cite their sources.
May reduce bleeding without increasing recurrent stroke in mild ischemic stroke; leaves open confirmation in randomized trials.
OBJECTIVES: The current study compared the safety and efficacy of long-term dual antiplatelet therapy (DAPT, aspirin plus clopidogrel) and intensive rosuvastatin with short-term DAPT for acute ischemic stroke (AIS). METHODS: A total of 220 patients were enrolled 72 h after the onset of mild to moderate AIS, and divided into a control group treated with 21-day DAPT and a study group treated with intensive rosuvastatin with 7-day DAPT on a voluntary basis. The primary outcome was recurrent ischemic stroke and hemorrhage during a 90-day follow-up period in an intention-to-treat analysis. The secondary outcome was clinical efficacy with respect to alleviating existing focal nerve defect symptoms. A Cox proportional-hazards model was used to evaluate treatment differences. RESULTS: Clinical efficacy was evident in 87.3% of patients in the study group, compared with 84.3% in the control group (p = 0.042). Recurrent ischemic stroke occurred in 9 patients (7.6%) in the study group and in 9 (8.8%) in the control group (p = 0.767). Hemorrhage occurred in 6 patients (5.1%) in the study group and in 15 (14.7%) in the control group (p = 0.023). In comparisons of levels of ALT, AST, LDH, and CK in the two groups before and 2 weeks after therapy, only CK differed significantly (p < 0.001). CONCLUSIONS: Compared to long-term DAPT, intensive rosuvastatin with short-term DAPT was equivalent in reducing the risk of recurrent ischemic stroke. It alleviated symptoms more rapidly, and significantly reduced the risk of bleeding, without causing an increase in transaminase or muscle enzymes. CLINICAL TRIAL REGISTRATION: China Clinical Trial Registration Center (ChiCTR1800017809).
No takes yet. Share an insight, caveat, or question.
Deng et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: